Antineoplastic agent, Phosphatidylinositol 3-kinase (PI3K) inhibitor Medicines in UAE
183 medicines available
About Antineoplastic agent, Phosphatidylinositol 3-kinase (PI3K) inhibitor Medicines
This page lists all Antineoplastic agent, Phosphatidylinositol 3-kinase (PI3K) inhibitor medicines available in UAE pharmacies.
Click on any medicine name to view detailed information including uses, dosage, side effects, and availability.
Complete List of Antineoplastic agent, Phosphatidylinositol 3-kinase (PI3K) inhibitor Medicines
Class:| Tyrosine kinase inhibitor
Use:| Treatment of advanced renal cell carcinoma, gastrointestinal stromal tumors after disease progression on or intolerance to imatinib, and pancreatic neuroendoc...
Class:| Tyrosine kinase inhibitor
Use:| Treatment of advanced renal cell carcinoma, gastrointestinal stromal tumor after disease progression on or intolerance to imatinib mesylate, and pancreatic ne...
Class:| Tyrosine kinase inhibitor
Use:| Treatment of advanced renal cell carcinoma, gastrointestinal stromal tumor after disease progression on or intolerance to imatinib, and pancreatic neuroendocr...
Class: | Tyrosine kinase inhibitor
Use: | Sunitinib Malate (SUTENT) is used for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate...
Class: | Tyrosine kinase inhibitor
Use: | Sunitinib Malate (SUTENT) is used for the treatment of gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylat...
Class:| Tyrosine kinase inhibitor
Use:| Treatment of advanced renal cell carcinoma, gastrointestinal stromal tumor after disease progression on or intolerance to imatinib, and pancreatic neuroendocr...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, particularly in those who have received at least one prior anti...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, especially in those who have received at least one prior anti-H...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, in combination with trastuzumab and capecitabine, who have rece...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, particularly in those who have received at least one prior anti...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, including those who have received one or more prior anti-HER2 t...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive metastatic breast cancer, including those with brain metastases, who have received at least one prior anti-HE...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, in combination with trastuzumab and capecitabine, who have rece...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, particularly in those who have received at least one prior anti...
Class: | Janus kinase (JAK) inhibitor
Use: | Treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adults; also approved for atopic dermatitis in certa...
Class: | Janus kinase (JAK) inhibitor
Use: | Treatment of moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis in adults; also indicated for atopic dermatitis in cert...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with HER2-positive locally advanced or metastatic breast cancer, in combination with other therapies
Adult dose: | 300 mg oral...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adult patients with unresectable locally advanced or metastatic HER2-positive breast cancer, in combination with capecitabine, particularly in ...
Class: | Janus kinase (JAK) inhibitor
Use: | Upadacitinib is indicated for the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and moderate t...
Class: | Janus kinase (JAK) inhibitor
Use: | Treatment of moderate to severe rheumatoid arthritis in adults, atopic dermatitis in adults and pediatric patients 12 years and older, and ulcerative col...
Class: | Janus kinase (JAK) inhibitor
Use: | Treatment of moderate to severe rheumatoid arthritis in adults, atopic dermatitis, and ulcerative colitis
Adult dose: | 45 mg once daily for rheumatoid...
Class: | Janus kinase (JAK) inhibitor
Use: | Treatment of moderate to severe rheumatoid arthritis in adults, atopic dermatitis in adults and pediatric patients 12 years and older, and ulcerative col...
Class: | Bruton's tyrosine kinase (BTK) inhibitor
Use: | Treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy; treatment of adult patients with ch...
Class: | Tyrosine kinase inhibitor
Use: | Treatment of adults with previously treated, advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement
Adult dose: | 13.5 mg o...
Class: | Kinase inhibitor
Use: | Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement
Adult dose:...
Class: | Kinase inhibitor
Use: | Treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement
Adult d...
Class: | Kinase inhibitor
Use: | Treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement
Adult dose:...